Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B-Reference-Cited by-同舟云学术

Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B

Published:2019-06-06 Issue:4 Volume:25 Page:
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Fukutake Katsuyuki¹²,Taki Masashi³,Matsushita Tadashi⁴,Sakai Michio⁵,Takata Ami⁶,Yamaguchi Hiromi⁶,Karumori Toshiyuki⁶^ORCID

Affiliation:

1. Department of Laboratory Medicine Tokyo Medical University Tokyo Japan

2. Department of Molecular Genetics of Coagulation Disorders Tokyo Medical University Tokyo Japan

3. Department of Pediatrics, St. Marianna University School of Medicine Yokohama City Seibu Hospital Yokohama Japan

4. Department of Transfusion Medicine Nagoya University Hospital Nagoya Japan

5. Department of Pediatrics University of Occupational and Environmental Health Kitakyushu Japan

6. Pfizer Japan Tokyo Japan

Funder

Pfizer Japan

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13783

Reference13 articles.

1. World Federation of Hemophilia. Report on the annual global survey 2016.http://www1.wfh.org/publications/files/pdf-1690.pdf. Accessed July 3 2018.

2. World Federation of Hemophilia. Guidelines for the Management of Hemophilia 2nd edition.http://www1.wfh.org/publications/files/pdf-1472.pdf. Accessed July 3 2018.

3. Medical and Scientific Advisory Council (MASAC). MASAC Recommendation Concerning Prophylaxis.https://www.hemophilia.org/sites/default/files/document/files/241Prophylaxis.pdf. Accessed July 3 2018.

4. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

5. Update on treatment regimens: Prophylaxis versus on-demand therapy

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Amount of Clotting Factor Concentrates Dispensed and Annual Medical Expenditures for Japanese Patients with Hemophilia B;Journal of Blood Medicine;2023-12

2. Real-World Use of Albutrepenonacog Alfa, A Recombinant Coagulation Factor IX Albumin Fusion Protein, for Personalized Prophylaxis in Japanese Individuals With Hemophilia B: A Case Series;Cureus;2023-01-09

3. Safety and effectiveness of Rixubis in patients with hemophilia B: a real-world, prospective, postmarketing surveillance study in South Korea;BLOOD RESEARCH;2020-12-31

4. Blood, blood components, plasma, and plasma products;Side Effects of Drugs Annual;2020

5. Nonacog alfa;Reactions Weekly;2019-08